• Mylan N.V.


  • Upjohn Inc.


The proposed combination of Mylan N.V. (Mylan) and Pfizer's Upjohn Inc. division (Upjohn), which will be renamed Viatris at the closing of the transaction (the proposed transaction).
Mylan and Upjohn both supply cardiovascular, neurology & pain, psychiatry, urology and ophthalmology pharmaceutical products in Australia.

Market definition

Refer to the attached Public Competition Assessment.

Competition analysis

Refer to the attached Public Competition Assessment.


Date Event

ACCC commenced review under the Merger Process Guidelines.

Closing date for submissions. The ACCC will place an indicative decision date here shortly.

ACCC awaiting further information from the parties. Former provisional date for announcement of ACCC's finding (11 June 2020) is delayed. ACCC will announce a proposed decision date in due course.

ACCC commenced market consultation on proposed s87B undertaking. ACCC timeline recommenced.

Closing date for submissions relating to the draft proposed divestment undertaking.

ACCC announced it would not oppose the proposed acquisition, subject to section 87B undertakings accepted by the ACCC.